{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epacadostat+%28INCB024360%29", "query": { "intervention": "Epacadostat (INCB024360)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 52, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epacadostat+%28INCB024360%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T04:25:00.378Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03006302", "title": "Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Epacadostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "CRS-207", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "GVAX Pancreas Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-01-31", "completion_date": "2024-08-05", "has_results": true, "last_update_posted_date": "2024-10-08", "last_synced_at": "2026-09-29T04:25:00.378Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03006302" }, { "nct_id": "NCT03322384", "title": "UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Lymphoma" ], "interventions": [ { "name": "epacadostat", "type": "DRUG" }, { "name": "SD-101", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2018-01-17", "completion_date": "2020-04-08", "has_results": true, "last_update_posted_date": "2022-02-01", "last_synced_at": "2026-09-29T04:25:00.378Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03322384" }, { "nct_id": "NCT04463771", "title": "Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "retifanlimab", "type": "DRUG" }, { "name": "epacadostat", "type": "DRUG" }, { "name": "pemigatinib", "type": "DRUG" }, { "name": "INCAGN02385", "type": "DRUG" }, { "name": "INCAGN02390", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 206, "start_date": "2021-01-26", "completion_date": "2026-05-29", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-09-29T04:25:00.378Z", "location_count": 29, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 26 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sylmar", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04463771" }, { "nct_id": "NCT03516708", "title": "Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Rectal Cancer" ], "interventions": [ { "name": "Epacadostat", "type": "DRUG" }, { "name": "Short-course radiation therapy", "type": "RADIATION" }, { "name": "CAPOX chemotherapy", "type": "DRUG" }, { "name": "FOLFOX chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2020-01-06", "completion_date": "2030-08-12", "has_results": false, "last_update_posted_date": "2026-02-11", "last_synced_at": "2026-09-29T04:25:00.378Z", "location_count": 4, "location_summary": "Orange, California • Boston, Massachusetts • Detroit, Michigan + 1 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03516708" }, { "nct_id": "NCT02752074", "title": "A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "pembrolizumab + epacadostat", "type": "DRUG" }, { "name": "pembrolizumab + placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 706, "start_date": "2016-06-21", "completion_date": "2019-08-16", "has_results": true, "last_update_posted_date": "2025-08-24", "last_synced_at": "2026-09-29T04:25:00.378Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02752074" }, { "nct_id": "NCT03402880", "title": "ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extensive Stage Small Cell Lung Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-10", "completion_date": "2018-10-03", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-09-29T04:25:00.378Z", "location_count": 3, "location_summary": "Duarte, California • South Pasadena, California • Boston, Massachusetts", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03402880" }, { "nct_id": "NCT02166905", "title": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Fallopian Tube Carcinoma", "Ovarian Carcinoma", "Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401", "type": "BIOLOGICAL" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Poly ICLC", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 40, "start_date": "2014-10-10", "completion_date": "2020-08-20", "has_results": true, "last_update_posted_date": "2023-02-24", "last_synced_at": "2026-09-29T04:25:00.378Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02166905" }, { "nct_id": "NCT02959437", "title": "Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors", "Advanced Malignancies", "Metastatic Cancer" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "INCB057643", "type": "DRUG" }, { "name": "INCB059872", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2017-02-27", "completion_date": "2020-03-02", "has_results": true, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-09-29T04:25:00.378Z", "location_count": 8, "location_summary": "Duarte, California • La Jolla, California • Chicago, Illinois + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02959437" }, { "nct_id": "NCT02559492", "title": "Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "INCB050465", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 142, "start_date": "2015-11", "completion_date": "2019-08-18", "has_results": false, "last_update_posted_date": "2019-09-25", "last_synced_at": "2026-09-29T04:25:00.378Z", "location_count": 11, "location_summary": "Duarte, California • Denver, Colorado • New Haven, Connecticut + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02559492" }, { "nct_id": "NCT03823131", "title": "Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Head and Neck Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Unresectable Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "ImmunoPulse", "type": "DEVICE" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "CORVax", "type": "BIOLOGICAL" }, { "name": "Tavokinogene telseplasmid", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG", "BIOLOGICAL" ], "sponsor": "Chase Heaton, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2019-05-02", "completion_date": "2022-07-31", "has_results": true, "last_update_posted_date": "2023-05-09", "last_synced_at": "2026-09-29T04:25:00.378Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03823131" } ] }